News | May 23, 2026
Gujarat Themis Biosyn acquires MicroBiopharm Japan for Rs. 1,300 Cr
Transition to a fermentation-based globally integrated CDMO platform
Transition to a fermentation-based globally integrated CDMO platform
SFDA nod marks company’s strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region
Organizations that embrace it thoughtfully today will help shape a healthier tomorrow, for India and beyond
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
BMS is moving beyond conversational AI into what it describes as “agentic” systems
The new facility at Byatarayanapura introduces Karnataka’s first Elekta Unity MR-Linac technology
The next-generation proteomics platform powered by Olink™ Explore HT enables simultaneous analysis of thousands of proteins from a single sample
Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
